Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QNRX
stocks logo

QNRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-4.020
-58.98%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Quoin Pharmaceuticals, Ltd. (QNRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 150.14%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+150.14%
In Past 3 Month
Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.910
sliders
Low
70.00
Averages
70.00
High
70.00
Current: 18.910
sliders
Low
70.00
Averages
70.00
High
70.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Quoin Pharmaceuticals Ltd (QNRX.O) is -1.85, compared to its 5-year average forward P/E of -1.10. For a more detailed relative valuation and DCF analysis to assess Quoin Pharmaceuticals Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.10
Current PE
-1.85
Overvalued PE
-0.03
Undervalued PE
-2.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.13
Current PS
0.00
Overvalued PS
0.74
Undervalued PS
-0.48
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

QNRX News & Events

Events Timeline

(ET)
2025-11-11
08:34:06
Quoin Reveals Success in Achieving Target Loadings for Rapamycin
select
2025-11-06 (ET)
2025-11-06
08:34:42
Quoin Pharmaceuticals projects financial stability through 2027
select
2025-11-06
08:34:19
Quoin Pharmaceuticals announces Q3 EPS of $6.71 compared to a loss of $16.29 in the previous year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-11NASDAQ.COM
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement

  • Stock Performance: Quoin Pharmaceuticals Ltd. (QNRX) saw a 21.15% increase in stock price, reaching $9.99, following the announcement of successful rapamycin loadings in their topical delivery platforms.

  • Clinical Development Plans: The company intends to manufacture clinical trial and stability batches in Q4 2025 and start clinical testing in the first half of 2026 for conditions like microcystic lymphatic malformations and venous malformations, which currently have no FDA-approved treatments.

  • Trading Activity: The announcement led to unusually high trading volume for QNRX, indicating strong investor interest in the company's developments.

  • Stock Range: The stock's 52-week price range is noted to be between $2.65 and $9.99.

[object Object]
Preview
4.5
11-11Benzinga
US Stocks Show Varied Performance; Sea Shares Rise Following Q3 Earnings Report

  • Market Performance: U.S. stocks showed mixed results, with the Dow up 0.13% while the Nasdaq fell 0.42% and the S&P 500 dropped 0.15%. Energy shares increased by 0.9%, but information technology stocks declined by 0.7%.

  • Company Highlights: Sea Ltd's shares rose 4% after reporting a 38.3% increase in quarterly revenue, despite missing earnings expectations. MSP Recovery Inc saw a significant 104% increase in its stock price.

  • Declining Stocks: Vor Biopharma Inc and Salarius Pharmaceuticals Inc experienced substantial drops of 48% and 50%, respectively, following announcements related to public offerings. Outset Medical Inc also fell 42% after disappointing financial results.

  • Global Market Trends: European shares rose, with the eurozone's STOXX 600 up 0.8%, while Asian markets closed mixed, with Japan's Nikkei 225 down slightly and India's BSE Sensex up 0.40%.

[object Object]
Preview
9.0
10-21Newsfilter
Quoin Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for QRX003 in Netherton Syndrome

  • FDA Approval and Orphan Drug Designation: Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for its product QRX003, aimed at treating Netherton Syndrome, following a similar designation from the EMA in May 2025.

  • Market Exclusivity and Benefits: If approved, QRX003 will enjoy seven years of marketing exclusivity in the U.S., along with benefits such as tax credits for clinical testing and reduced FDA application fees.

  • Clinical Trials and Development Timeline: QRX003 is currently being evaluated in two late-stage pivotal clinical trials, with enrollment expected to complete by Q1 2026 and top-line data anticipated in the second half of 2026.

  • Company Commitment: Quoin Pharmaceuticals emphasizes its dedication to advancing QRX003's clinical development to address the unmet medical needs of patients suffering from Netherton Syndrome and other rare diseases.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quoin Pharmaceuticals Ltd (QNRX) stock price today?

The current price of QNRX is 18.91 USD — it has increased 6.09 % in the last trading day.

arrow icon

What is Quoin Pharmaceuticals Ltd (QNRX)'s business?

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

arrow icon

What is the price predicton of QNRX Stock?

Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quoin Pharmaceuticals Ltd (QNRX)'s revenue for the last quarter?

Quoin Pharmaceuticals Ltd revenue for the last quarter amounts to -4.02M USD, increased 59.02 % YoY.

arrow icon

What is Quoin Pharmaceuticals Ltd (QNRX)'s earnings per share (EPS) for the last quarter?

Quoin Pharmaceuticals Ltd. EPS for the last quarter amounts to -2225459.00 USD, increased 2.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quoin Pharmaceuticals Ltd (QNRX)'s fundamentals?

The market is revising No Change the revenue expectations for Quoin Pharmaceuticals, Ltd. (QNRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 150.14%.
arrow icon

How many employees does Quoin Pharmaceuticals Ltd (QNRX). have?

Quoin Pharmaceuticals Ltd (QNRX) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Quoin Pharmaceuticals Ltd (QNRX) market cap?

Today QNRX has the market capitalization of 14.95M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free